Wells Fargo analyst Jim Birchenough last night upgraded Bellicum Pharmaceuticals to Outperform from Market Perform and raised his price target for the shares to $23 from $6. The shares in premarket trading are up 27% to $8.70 following news that the FDA lifted the clinical hold on studies of BPX-501 in the U.S. Rapid resolution of the clinical hold "substantially de-risks the investment," Birchenough tells investors in a research note. He believes Bellicum's platform for controllable cell therapies is well positioned for therapeutic oncology indications.